As of November 6, 2026, Eli Lilly and Company (LLY) trades at $1354.00. Equity Rank's blended estimate across 10 valuation models with sufficient data is $663.67 — a model fair value differential of 51.0% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.
Source: Equity Rank — LLY fair value (data as of 2026-11-06). The full page adds the per-method breakdown and the model’s scenario range (with an Equity Rank account).
Reported EPS came in above the analyst estimate in 7 of the last 8 reports. The median share-price change across a report, in either direction, was 8.2%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Oct 29, 2026 | $5.38 | $7.48 | +39.0% | +6.6% |
| Aug 5, 2026 | $6.01 | $8.38 | +39.4% | +4.9% |
| Apr 30, 2026 | $6.79 | $8.55 | +25.9% | +9.8% |
| Feb 4, 2026 | $7.17 | $7.54 | +5.2% | +10.3% |
| Oct 30, 2025 | $5.89 | $7.02 | +19.2% | +3.8% |
| Aug 7, 2025 | $5.61 | $6.31 | +12.5% | -14.1% |
| May 1, 2025 | $3.46 | $3.34 | -3.5% | -11.7% |
| Feb 6, 2025 | $5.07 | $5.32 | +5.0% | +3.4% |
Equity Rank computed model fair value for LLY from 10 independent valuation methods with sufficient data. 1 place fair value above the current price of $1354.00, and 9 place it below. The model-blended estimate lands at $663.67 — a model fair value differential of 51.0% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores LLY at 79.2/100 (A-, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +24.9% per year and gross margin has moved +6.3 pp. Its SAVE composite score has moved +0.2 over the past 30 days.
Equity Rank's intrinsic value estimate for Eli Lilly and Company (LLY) — the model fair value — is $663.67 as of November 6, 2026, blended from 10 valuation methods with sufficient data. An intrinsic value estimate is what the models compute a share to be worth under stated assumptions; it is not a price target, not a prediction of where the stock will trade, and not investment advice.
Equity Rank calculates fair value for LLY by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Eli Lilly and Company (LLY) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Eli Lilly and Company (LLY) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
More on LLY: Is LLY overvalued? · If you had invested $1,000 in LLY · LLY dividend income
Side-by-side valuation: LLY vs PFE · LLY vs MRK · LLY vs JNJ · LLY vs ABBV · LLY vs NVS · LLY vs AZN
ETFs holding LLY (share of fund): XLV (16.5%) · VIG (4.1%) · QUAL (3.6%) · IWF (3.1%) · SPYG (2.7%) · VUG (2.6%)
All General Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/LLY. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of November 6, 2026 and are recomputed after every U.S. market close.